S&P Futures
4,157.50-5.00(-0.12%)Dow Futures
33,910.00-13.00(-0.04%)Nasdaq Futures
13,977.25-36.75(-0.26%)
Mind Cure Health Inc. (MCURF)
Chart Events
Performance Outlook
| Previous Close | 0.3350 |
| Open | 0.3300 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.3209 - 0.3580 |
| 52 Week Range | 0.3200 - 0.6310 |
| Volume | 331,999 |
| Avg. Volume | 475,811 |
| Market Cap | 17.001M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- CNW Group
MINDCURE Announces The Addition of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience in Medical Psychoactive Segment
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the addition of Daniel Herrera as Vice President, Growth and Strategic Partnerships. Mr. Herrera joins the company with extensive experience in the life sciences industry, where he has led teams and divisions at high-growth start-ups as well as large multinational pharmaceutical companies.
- CNW Group
MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company's Psychedelic Digital Therapeutics Technology Platform
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has entered into a partnership with Speak Ai Inc. ("Speak Ai"). The Canadian-based technology company helps individuals and organizations analyze media, language, and metadata to automatically generate valuable insights through machine learning. MINDCURE will be integrating the platform's capabilities into iSTRYM, and will also work with Speak Ai to develop proprietary, technology-based mental health solutions.
- PR Newswire
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce a further strategic equity investment in ATMA Journey Centers Inc. ("ATMA"). This follow-on investment enables MINDCURE to retain its 13% ownership of ATMA, in accordance with the terms of the letter of intent (the "LOI") announced on January 12, 2021. Additionally, MINDCURE President and CEO Kelsey Ramsden will be joining the ATMA Board of Directors.
